Main Session
Sep
30
SH 07 - Head and Neck Cancer - Science Highlights
LBA 06 - NRG-HN009 Randomized Phase II/III Trial of RT + Cisplatin Q3 Weeks vs RT + Cisplatin Weekly for Patients with Locoregionally Advanced SCCHN: p16-Negative Phase II Toxicity Results
Presenter(s)
Paul Harari, MD, FASTRO - University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin